Dynavax Technologies Intrinsic Value Calculator – Dynavax Technologies Reaches 80+ Relative Strength Rating Milestone
December 2, 2023
☀️Trending News
Dynavax Technologies ($NASDAQ:DVAX) is a biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapy agents to address significant unmet medical needs. Recently, the company has achieved a significant milestone by reaching an impressive Relative Strength Rating of over 80. The Relative Strength Rating is a measure of a stock’s performance over the past year, with higher numbers representing better performance. With this rating, Dynavax Technologies is now one of the top-performing stocks on the market, making it an attractive investment opportunity for investors.
The company is also actively involved in research and development of new drugs and treatments, making it well-positioned to capitalize on potential medical breakthroughs. Now that the company has achieved such a strong Relative Strength Rating, its position as a leader in the biopharmaceutical industry is even more secure.
Market Price
On Tuesday, DYNAVAX TECHNOLOGIES achieved a significant milestone as their stock reached an 80+ relative strength rating. The stock opened the day at $13.6 and closed at $13.3, a drop of 2.6% from its previous closing price. This performance is a testament to the success of the company’s recent business strategies and their commitment to creating value for their shareholders.
Despite the slight dip in stock price, investors remain confident in DYNAVAX TECHNOLOGIES’ future growth prospects as they continue to expand and diversify their offerings. This news is an exciting development for both current and potential shareholders and is expected to positively impact the long-term performance of the company. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Dynavax Technologies. More…
| Total Revenues | Net Income | Net Margin |
| 361.18 | 61.13 | 20.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Dynavax Technologies. More…
| Operations | Investing | Financing |
| 152.18 | -316 | 19.52 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Dynavax Technologies. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 972.93 | 368.02 | 4.48 |
Key Ratios Snapshot
Some of the financial key ratios for Dynavax Technologies are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 112.6% | – | 19.2% |
| FCF Margin | ROE | ROA |
| 40.8% | 7.5% | 4.5% |
Analysis – Dynavax Technologies Intrinsic Value Calculator
GoodWhale is here to help you analyze the financials of DYNAVAX TECHNOLOGIES. Our proprietary Valuation Line has calculated a fair value of roughly $11.2 for DYNAVAX TECHNOLOGIES shares. However, the current share price of $13.3 is overvalued by 18.3%. This means that now may not be the best time to buy DYNAVAX TECHNOLOGIES stock. However, investors should keep an eye on the stock, as it may become more attractive if the market corrects in the near future. More…
Peers
The market for Dynavax Technologies Corp is quite competitive. The company’s main competitors are Foresee Pharmaceuticals Co Ltd, Aeolus Pharmaceuticals Inc, and Kala Pharmaceuticals Inc. All of these companies are vying for a share of the market, and each has its own strengths and weaknesses. Dynavax Technologies Corp must keep an eye on all of its competitors in order to stay ahead in the market.
– Foresee Pharmaceuticals Co Ltd ($TPEX:6576)
Foresee Pharmaceuticals Co Ltd is a pharmaceutical company with a market cap of 8.77B as of 2022. The company has a Return on Equity of -22.28%. The company focuses on the development and commercialization of innovative drugs for the treatment of cancer and other diseases. The company’s products include F-76, a phase III clinical candidate for the treatment of ovarian cancer; and F-288, a phase II clinical candidate for the treatment of solid tumors. Foresee Pharmaceuticals Co Ltd was founded in 2007 and is headquartered in Taipei, Taiwan.
– Aeolus Pharmaceuticals Inc ($OTCPK:AOLS)
Aeolus Pharmaceuticals Inc is a pharmaceutical company that focuses on the development of treatments for a variety of conditions. The company’s market cap is $167.29k and its ROE is -383.62%. Aeolus Pharmaceuticals Inc’s main product is a treatment for a condition called idiopathic pulmonary fibrosis. The company is also developing treatments for other conditions, including cancer and Alzheimer’s disease.
– Kala Pharmaceuticals Inc ($NASDAQ:KALA)
Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of eye diseases. The company’s lead product candidate, KPI-121, is a topical ocular formulation of loteprednol etabonate in development for the treatment of pain and inflammation associated with ocular surgery. Kala Pharmaceuticals Inc has a market cap of 7.69M as of 2022, a Return on Equity of 435.55%. The company’s focus on the development and commercialization of therapies for the treatment of eye diseases makes it a promising investment for those interested in the healthcare sector.
Summary
Dynavax Technologies Corporation is a biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax has recently achieved a relative strength rating of above 80, meaning it has outperformed 80% of stocks within its peer group over the past year. This is an indication that Dynavax is trending towards a strong performance in the stock market. Investors should consider Dynavax’s potential as a long-term investment due to its promising portfolio of products and pipeline of new therapies.
Furthermore, Dynavax is well-positioned to capitalize on its valuable intellectual property and expertise in immunology. Analysts are optimistic about Dynavax’s growth prospects due to its potential for long-term returns in the immunology space.
